Volition Veterinary Presents Expert Report Ahead of First Product Launch

• A Look to the Future of Cancer Diagnostics compiles insight from four veterinary cancer experts
• Report provides insight into the clinical impact of early cancer detection, and recent advances
• Experts also reviewed data on the Nu.Q™ Vet Cancer Screening Test, providing opinion and guidance ahead of expected launch
• Download a copy of the report here

AUSTIN, Nov. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has published a report with contributions from four global leaders in veterinary oncology, ahead of the expected launch of its first product, the Nu.Q™ Vet Cancer Screening Test.

The comprehensive new report for veterinarians, titled A Look to the Future of Cancer Diagnostics, explores the promise of molecular diagnostics in veterinary oncology, especially for hard to find tumors, and introduces Volition’s Nu.Q™ technology and Nu.Q™ Vet Cancer Screening Test.

The report is the outcome of a round table event, hosted by Volition Veterinary Diagnostics Development, LLC, with an expert panel including: Dr. Tim Fan Ph.D., DVM, DACVIM, Program Leader, Cancer Discovery Platforms and Professor, Veterinary Clinical Medicine, at the Cancer Center at Illinois; Dr. David Vail DVM, DACVIM, Professor and Barbara A. Suran Chair in Comparative Oncology, and Director of the Barbara A. Suran Comparative Oncology Research Center; and Dr. Sue Ettinger DVM, DACVIM, a practicing veterinary cancer specialist, international speaker and author. Dr. Heather Wilson-Robles DVM, DACVIM, Professor of Oncology at Texas A&M University and Chief Medical Officer at Volition Veterinary was also a panelist.

The panel reviewed data from results presented at the Veterinary Cancer Society Virtual Annual Conference in October, which demonstrated the successful use of the blood-based Nu.Q™ Vet Cancer Screening Test for dogs with lymphoma and hemangiosarcoma, a cancer of blood vessel walls, which together make up approximately one-third of canine cancers. They also discussed topics including the potential of early cancer diagnosis to help improve the treatment and quality of life, as well as supporting the clinical decision-making process.

“I was very pleased to participate in the round table and the subsequent report,” Dr. Tim Fan commented. “Volition’s platform is very exciting. Nucleosomes are very stable biomarkers that can be found in circulation and bringing this technology to the veterinary market is a very important first step. I look forward to seeing Volition adapt to the needs of the clients, pets and pet-owners that will benefit from this diagnostic test.”

Dr. Heather Wilson-Robles said: “Dr. Fan, Dr. Vail and Dr. Ettinger are leading the field in veterinary oncology. I am hugely grateful for their insight, expert opinion and guidance at this key moment as we prepare for the launch of our first product and take on the challenge of earlier detection of canine cancers. Cancer screening is not as commonplace in animal health as it is in human health, but blood tests like the Nu.Q™ Vet Cancer Screening Test could transform how we manage cancer in companion animals.”

To learn more about Volition Veterinary, Nu.Q™ Vet please visit our new webpage at https://volition.com/veterinary or download a copy of the report, A Look to the Future of Cancer Diagnostics here.

About the Nu.Q™ Vet Cancer Screening Test

Cancer is the most common cause of death in dogs over the age of two years old in the U.S. and up to 50% of all dogs over the age of 10 develop cancer in their lifetime. Together, Lymphoma and Hemangiosarcoma make up approximately one third of canine cancers. Currently, dogs suspected of having cancer are required to undergo a variety of diagnostic tests that may be expensive, time consuming and/or painful for the animal. The Nu.Q™ Vet Cancer Screening Test is a low-cost, easy to use ELISA-based screening test that measures and identifies circulating nucleosomes, which are early markers of cancer, from a simple blood sample to enable a streamlined and less invasive diagnostic process.

About Volition

Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.

Volition’s research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics™ and Nu.Q™ and their respective logos are trademarks of Volition and its subsidiaries.

For more information about Volition, visit Volition’s website (www.volition.com) or connect with us via:

Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx

The contents found at Volition’s website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition’s website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing of the commercial launch of Volition’s test platforms for early detection of cancer and other diseases. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic or prognostic products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

View original content to download multimedia:http://www.prnewswire.com/news-releases/volition-veterinary-presents-expert-report-ahead-of-first-product-launch-301169621.html

SOURCE VolitionRx Ltd

Company Codes: AMEX:VNRX